Salarius Pharmaceuticals Inc (SLRX) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.89x
Salarius Pharmaceuticals Inc (SLRX) has a Cash Flow-to-Debt Ratio of -0.89x as of September 2025, meaning its operating cash flow of $-1.65 Million could theoretically repay -1% of its total liabilities ($1.85 Million) in one year. See SLRX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.89x
Operating CF / Total Liabilities
Operating Cash Flow
$-1.65 Million
USD
Total Liabilities
$1.85 Million
USD
Data as of
Sep 2025
Most recent filing
Salarius Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Salarius Pharmaceuticals Inc across 10 annual periods. For the full cash flow conversion analysis, see Salarius Pharmaceuticals Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Salarius Pharmaceuticals Inc (2015–2024)
Year-by-year debt coverage analysis for Salarius Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.99x | $-4.53 Million | $1.51 Million | ▲ +69.7% |
| 2023 | -9.89x | $-12.85 Million | $1.30 Million | ▼ -139.7% |
| 2022 | -4.12x | $-17.60 Million | $4.27 Million | ▲ +14.6% |
| 2021 | -4.83x | $-10.20 Million | $2.11 Million | ▼ -30.0% |
| 2020 | -3.72x | $-10.31 Million | $2.77 Million | ▼ -6.4% |
| 2019 | -3.49x | $-11.58 Million | $3.31 Million | ▲ +83.6% |
| 2018 | -21.32x | $-23.60 Million | $1.11 Million | ▼ -352.7% |
| 2017 | -4.71x | $-27.72 Million | $5.89 Million | ▲ +42.7% |
| 2016 | -8.22x | $-32.05 Million | $3.90 Million | ▼ -14.1% |
| 2015 | -7.21x | $-20.75 Million | $2.88 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.